{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T03:16:27Z","timestamp":1773890187132,"version":"3.50.1"},"reference-count":10,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01CA298333"],"award-info":[{"award-number":["R01CA298333"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","eu-focus.europeanurology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology Focus"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.euf.2025.11.014","type":"journal-article","created":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T12:22:45Z","timestamp":1764850965000},"page":"49-50","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Urothelial Cancer: What Is the Role of Expression-based Subtypes to Guide Neoadjuvant Therapy in Muscle-invasive Bladder Cancer?"],"prefix":"10.1016","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5444-5510","authenticated-orcid":false,"given":"Joshua J.","family":"Meeks","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.euf.2025.11.014_b0005","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.cell.2017.09.007","article-title":"Comprehensive molecular characterization of muscle-invasive bladder cancer","volume":"171","author":"Robertson","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.euf.2025.11.014_b0010","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3233\/BLC-200306","article-title":"Tumor subtyping: making sense of heterogeneity with a goal toward treatment","volume":"7","author":"Meeks","year":"2021","journal-title":"Bladder Cancer"},{"key":"10.1016\/j.euf.2025.11.014_b0015","doi-asserted-by":"crossref","first-page":"5082","DOI":"10.1158\/1078-0432.CCR-18-1106","article-title":"Divergent biological response to neoadjuvant chemotherapy in muscle-invasive bladder cancer","volume":"25","author":"Seiler","year":"2019","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.euf.2025.11.014_b0020","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.annonc.2024.09.008","article-title":"Basal\/squamous and mixed subtype bladder cancers present poor outcomes after neoadjuvant chemotherapy in the VESPER trial","volume":"36","author":"Groeneveld","year":"2025","journal-title":"Ann Oncol"},{"key":"10.1016\/j.euf.2025.11.014_b0025","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.euros.2024.12.009","article-title":"Molecular subtyping for predicting pathological upstaging and survival outcomes in clinically organ-confined bladder cancer patients undergoing radical cystectomy","volume":"73","author":"de Jong","year":"2025","journal-title":"Eur Urol Open Sci"},{"key":"10.1016\/j.euf.2025.11.014_b0030","doi-asserted-by":"crossref","DOI":"10.1002\/2056-4538.12363","article-title":"Verification of molecular subtyping of bladder cancer in the GUSTO clinical trial","volume":"10","author":"Griffin","year":"2024","journal-title":"J Pathol Clin Res"},{"key":"10.1016\/j.euf.2025.11.014_b0035","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2024.42.16_suppl.TPS4621","article-title":"Use of gene expression patterns to identify unique molecular subtypes in muscle invasive bladder cancer: GUSTO","volume":"42","author":"Crabb","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euf.2025.11.014_b0040","doi-asserted-by":"crossref","first-page":"5123","DOI":"10.1158\/1078-0432.CCR-20-4175","article-title":"Heterogeneity in NECTIN4 expression across molecular subtypes of urothelial cancer mediates sensitivity to enfortumab vedotin","volume":"27","author":"Chu","year":"2021","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.euf.2025.11.014_b0045","doi-asserted-by":"crossref","unstructured":"Jindal T, Jiang CY, Alhalabi O, et al. Outcomes with enfortumab vedotin in patients with histologic subtypes of advanced urothelial carcinoma: analysis of the UNITE study. Eur Urol. In press. https:\/\/doi.org\/10.1016\/j.eururo.2025.09.003.","DOI":"10.1016\/j.eururo.2025.09.003"},{"key":"10.1016\/j.euf.2025.11.014_b0050","series-title":"LBA2\u2014Perioperative (periop) enfortumab vedotin (EV) plus pembrolizumab (pembro) in participants (pts) with muscle-invasive bladder cancer (MIBC) who are cisplatin-ineligible: the phase III KEYNOTE-905 study","author":"Vulsteke","year":"2025"}],"container-title":["European Urology Focus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405456925003463?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405456925003463?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T23:52:03Z","timestamp":1773877923000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405456925003463"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":10,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["S2405456925003463"],"URL":"https:\/\/doi.org\/10.1016\/j.euf.2025.11.014","relation":{},"ISSN":["2405-4569"],"issn-type":[{"value":"2405-4569","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Urothelial Cancer: What Is the Role of Expression-based Subtypes to Guide Neoadjuvant Therapy in Muscle-invasive Bladder Cancer?","name":"articletitle","label":"Article Title"},{"value":"European Urology Focus","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euf.2025.11.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 European Association of Urology. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}